2 results
Approved WMOCompleted
Valemetostat tosylate may modify epigenetic changes, which plays an important role in the pathogenesis of PTCL. In the ongoing open-label Phase 1 study (DS3201-A-J101, 25 Dec 2019 data cut-off), valemetostat tosylate monotherapy demonstrated…
Approved WMOCompleted
Objective: The aim of this study is to evaluate if an adequate level of bowel cleansing can be achieved with the Pure-Vu in patients with previous poor bowel preparation (Boston Bowel Preparation Scale [BBPS]<6).